Septerna, Inc. SEPN R2K
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -25.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SEPN Septerna, Inc. R2K | 30.20 | - | $1.36B | - | -15.87% | -9.26% | - | -25.54% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 33.00K | 317.00K | 370.00K | - | 219.00K | 119.00K | 21.50M | 24.12M | 26.52M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 26.13M | 29.10M | 31.38M | 40.14M | 39.82M |
| Operating Income | - | - | -12.04M | -15.49M | -18.07M | - | -25.91M | -28.98M | -9.89M | -16.02M | -13.30M |
| EBITDA | - | - | - | - | - | - | -25.51M | -28.57M | -9.48M | -15.62M | -12.88M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -21.48M | -24.84M | 8.17M | -10.73M | -8.30M |
| Tax Provision | - | - | - | - | - | - | 0 | 0 | 0 | 12.00K | 337.00K |
| Net Income | -9.17M | -10.60M | -10.95M | -14.10M | -16.51M | - | -21.48M | -24.84M | 8.17M | -10.74M | -8.64M |
| Diluted EPS | - | - | -5.45 | -6.35 | -7.03 | - | -0.49 | -0.56 | 0.18 | -0.24 | -0.19 |
| R&D Expense | - | - | 9.28M | 13.15M | 15.04M | 17.83M | 19.27M | 22.19M | 24.26M | - | 29.54M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 151.00K | 1.07M | 45.95M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 27.97M | 45.70M | 81.90M | 126.75M |
| Operating Income | -27.97M | -45.55M | -80.82M | -80.80M |
| EBITDA | -27.39M | -44.70M | -79.42M | -79.19M |
| Interest Expense | - | - | - | - |
| Pretax Income | -27.68M | 4.87M | -72.30M | -48.87M |
| Tax Provision | 0 | 691.00K | -498.00K | 12.00K |
| Net Income | -27.68M | 4.18M | -71.80M | -48.88M |
| Diluted EPS | -1.42 | 0.03 | -7.26 | - |
| R&D Expense | - | 35.98M | 65.34M | 97.58M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -25.54% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +226.49% |
| 6 Months: | +7.97% |
| 3 Months: | +4.07% |
| 1 Month: | +28.78% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 36.12M | 130.87M | 456.55M | 596.19M |
| Current Assets | 31.89M | 112.68M | 356.82M | 410.96M |
| Cash & Equivalents | 30.61M | 88.48M | 238.20M | 120.72M |
| Inventory | - | - | - | - |
| Receivables | 0 | 151.00K | 171.00K | 10.36M |
| Total Liabilities | 80.32M | 169.24M | 36.51M | 214.26M |
| Current Liabilities | 5.54M | 6.91M | 12.85M | 86.93M |
| Long Term Debt | - | - | - | - |
| Total Debt | 710.00K | 12.57M | 25.48M | 23.62M |
| Total Equity | -44.20M | -38.37M | 420.05M | 381.93M |
| Shares Outstanding | 42.00M | 42.00M | 44.42M | 44.81M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -23.30M | -38.72M | -67.47M | 110.19M |
| Investing Cash Flow | -1.29M | 22.12M | -160.60M | -229.35M |
| Financing Cash Flow | 30.05M | 74.52M | 377.78M | 1.69M |
| Capital Expenditure | -1.29M | -2.88M | -2.10M | -518.00K |
| Free Cash Flow | -24.59M | -41.60M | -69.57M | 109.67M |
| Net Change in Cash | 5.46M | 57.92M | 149.71M | -117.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | -30,165.6% | -7,518.4% | -175.8% |
| Net Margin % | - | 2,768.2% | -6,678.9% | -106.4% |
| ROE % | 62.6% | -10.9% | -17.1% | -12.8% |
| ROCE % | -91.5% | -36.7% | -18.2% | -15.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 15.52% | 7.00M | $211.27M |
| 2 | Trv Gp V, LLC | 13.79% | 6.22M | $187.71M |
| 3 | Driehaus Capital Management, LLC | 9.75% | 4.40M | $132.75M |
| 4 | Trv Gp VI, LLC | 9.34% | 4.21M | $127.19M |
| 5 | Samsara BioCapital, LLC | 6.99% | 3.15M | $95.10M |
| 6 | Goldman Sachs Group Inc | 6.45% | 2.91M | $87.77M |
| 7 | Siren, L.L.C. | 4.44% | 2.00M | $60.40M |
| 8 | Blackrock Inc. | 4.04% | 1.82M | $55.03M |
| 9 | BVF Inc. | 3.00% | 1.35M | $40.87M |
| 10 | Avoro Capital Advisors LLC | 2.97% | 1.34M | $40.39M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SEPN